- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADVANCED BIOMED Aktie jetzt für 0€ handeln | |||||
| 26.02. | Advanced Biomed Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Advanced Biomed announces 1-for-20 reverse stock split to regain Nasdaq compliance | 1 | Investing.com | ||
| 18.02. | Advanced Biomed Inc. Announces 1 for 20 Share Consolidation | 118 | GlobeNewswire (Europe) | Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the "Company" or "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative... ► Artikel lesen | |
| 13.02. | Advanced Biomed Inc. Announces 120-Case Feasibility Study with Chi-Mei Medical Center to Validate A+PerfusC - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery | 2 | GlobeNewswire (USA) | ||
| 02.02. | Advanced Biomed Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.01. | Advanced Biomed Inc. regelt Schuldenrückzahlung von Tochtergesellschaft in Nachtragsvereinbarung | 1 | Investing.com Deutsch | ||
| 21.01. | Advanced Biomed Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.12.25 | Advanced Biomed Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.12.25 | Advanced Biomed-Aktie steigt nach Verkauf von Hongkong-Tochter | 1 | Investing.com Deutsch | ||
| 30.12.25 | Advanced Biomed veräußert Hongkong-Tochter für 23.000 US-Dollar | 1 | Investing.com Deutsch | ||
| 30.12.25 | Advanced Biomed sells Hong Kong subsidiary for $23,000 | 1 | Investing.com | ||
| 30.12.25 | Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary | 293 | GlobeNewswire (Europe) | Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative... ► Artikel lesen | |
| 19.11.25 | Advanced Biomed Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | Advanced Biomed Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 08.10.25 | Advanced Biomed Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 30.09.25 | Advanced Biomed Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 19.09.25 | Advanced Biomed Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.09.25 | Advanced Biomed Inc. Announces Launch of A+PerfusC - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery | 1 | GlobeNewswire (USA) | ||
| 07.03.25 | Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering | 655 | GlobeNewswire (Europe) | Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and... ► Artikel lesen | |
| 06.03.25 | Advanced Biomed Inc. Announces Pricing of Initial Public Offering | 448 | GlobeNewswire (Europe) | Tainan, Taiwan, March 06, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company" or "Advanced Biomed"), a biotechnology company focused on early screening and detection, diagnosis and staging... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 47,610 | -1,18 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius mit einem Kursziel von 56 Euro auf "Buy" belassen. Analyst Falko Friedrichs lobte in seiner am Donnerstag vorliegenden... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 18,860 | -1,77 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,120 | -1,34 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,180 | +0,08 % | BARCLAYS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für FMC von 47,50 auf 46,50 Euro gesenkt und die Einstufung auf "Equal Weight" belassen. Das Wachstum der Behandlungszahlen... ► Artikel lesen | |
| PROGYNY | 17,800 | +1,60 % | INVO Fertility, Inc.: INVO Fertility's Wisconsin Clinic Joins Progyny Network | ||
| PROCEPT BIOROBOTICS | 26,600 | +2,62 % | Truist cuts Procept BioRobotics stock price target on lower forecasts | ||
| LIFESTANCE HEALTH GROUP | 7,325 | +2,45 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| HEARTFLOW | 23,910 | +2,44 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| INNOVAGE | 10,610 | +14,46 % | InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025 | DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ("InnovAge" or the "Company") (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly... ► Artikel lesen | |
| NEUROPACE | 13,960 | -1,34 % | Why NeuroPace Stock Was Inching Higher on Wednesday | ||
| PRIVIA HEALTH GROUP | 24,310 | +1,21 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen | |
| BETA BIONICS | 11,380 | -6,80 % | Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 | IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| TALKSPACE | 4,930 | +1,75 % | Talkspace Announces Fourth Quarter and Full Year 2025 Results | 4Q 2025 total revenue grew 29% year-over-year to $63.0 million4Q 2025 net income of $4.8 million and adjusted EBITDA1 of $6.6 million Full-year 2025 total revenue grew 22% year-over-year to $228.9... ► Artikel lesen | |
| ADAPTHEALTH | 9,670 | +0,36 % | Leerink cuts AdaptHealth stock price target on 2025 earnings decline | ||
| GERRESHEIMER | 17,120 | -0,17 % | Gerresheimers Abschluss unter dem Röntgenblick der BaFin | Die BaFin verschärft den Blick auf die Rechnungslegung der Gerresheimer AG. Sie kündigt an, die am 18.09.2025 gestartete Anlassprüfung des offengelegten Konzernabschlusses und Konzernlageberichts 2023/2024... ► Artikel lesen |
Das Unternehmen ADVANCED BIOMED INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVANCED BIOMED INC finden Sie auf Wallstreet Online.